Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events

被引:42
作者
Zhen, Z [1 ]
Espinoza, Y [1 ]
Bleu, T [1 ]
Sommer, JM [1 ]
Wright, JF [1 ]
机构
[1] Avigen Inc, Alameda, CA 94502 USA
关键词
D O I
10.1089/1043034041361262
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A highly sensitive assay for determination of infectious titers of recombinant adeno-associated virus (AAV) by limiting dilution analysis is described. This assay is capable of detecting single infectious events and can therefore provide an absolute rather than relative measure of infectivity. The assay utilizes a HeLa-derived AAV2 Rep/Cap-expressing cell line, D7-4, grown in 96-well plates and infected with replicate 10-fold serial dilutions of AAV2 vectors in the presence of adenovirus type 5. Forty-eight hours after infection, vector genome replication is determined by quantitative PCR (Q-PCR). A linear relationship between vector genome input and replicated copy number (slope = 2670 copies per vector genome) was determined, enabling detection of one infectious event per well by Q-PCR. The observed binomial distribution of the end-point data confirmed that single infectious events could be detected, and allowed calculation of infectious titers by the Karber method. Analysis of an AAV2 reference vector, AAV-hFIX16, in 21 independent determinations gave an average ratio of AAV vector genomes (VG) to infectious units (IU) of 8.3 +/- 4.2 VG/IU, a value close to the theoretical limit. No significant differences in vector particle-to-infectious unit ratios were observed between vectors purified by column chromatography (9.3 +/- 5.0 VG/IU, n = 7) and cesium chloride gradient ultracentrifugation (6.4 +/- 3.2 VG/IU, n = 7).
引用
收藏
页码:709 / 715
页数:7
相关论文
共 20 条
[1]   A high-throughput hybridization method for titer determination of viruses and gene therapy vectors [J].
Atkinson, EM ;
Debelak, DJ ;
Hart, LA ;
Reynolds, TC .
NUCLEIC ACIDS RESEARCH, 1998, 26 (11) :2821-2823
[2]   Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors [J].
Bartlett, JS ;
Wilcher, R ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 2000, 74 (06) :2777-2785
[3]   QUICK-BLOT - SELECTIVE MESSENGER-RNA OR DNA IMMOBILIZATION FROM WHOLE CELLS [J].
BRESSER, J ;
DOERING, J ;
GILLESPIE, D .
DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY, 1983, 2 (03) :243-254
[4]  
CALLAHAN DJ, 2002, BIOPROC J, V1, P43
[5]   CELL-LINES FOR THE PRODUCTION OF RECOMBINANT ADENOASSOCIATED VIRUS [J].
CLARK, KR ;
VOULGAROPOULOU, F ;
FRALEY, DM ;
JOHNSON, PR .
HUMAN GENE THERAPY, 1995, 6 (10) :1329-1341
[6]   Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses [J].
Clark, KR ;
Liu, XL ;
McGrath, JP ;
Johnson, PR .
HUMAN GENE THERAPY, 1999, 10 (06) :1031-1039
[7]   High throughput production, screening and analysis of adeno-associated viral vectors [J].
Drittanti, L ;
Rivet, C ;
Manceau, P ;
Danos, O ;
Vega, M .
GENE THERAPY, 2000, 7 (11) :924-929
[8]   Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6 [J].
Grimm, D ;
Kay, MA ;
Kleinschmidt, JA .
MOLECULAR THERAPY, 2003, 7 (06) :839-850
[9]   AAV-mediated gene transfer for hemophilia [J].
High, KA .
NEW VISTAS IN THERAPEUTICS, FROM DRUG DESIGN TO GENE THERAPY: DRUG-RESISTANT TUBERCULOSIS, FROM MOLECULES TO MACRO-ECONOMICS, 2001, 953 :64-74
[10]  
Huang J., 2000, MOL THER, V1, pS286